In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
Related to this article
FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
2
Phase 1 Data: SNTX-2643 Blunts the Brain's Stress Response After a Single Dose
3
Early Brenipatide Data Shows Substance Use Treatment Potential
4
Embodied Technologies for Mental Health: Leveraging Synthetic Emotions for Dissociation and Anhedonia
5